Neprilysin

Neprilysin Molekülinformation

Englischer Name	Neprilysin	Anzahl der inverkehr gebrachten Arzneimittel	3
Anzahl der klinischen Arzneimittel	8	Target-Alias	EC:3.4.24.11，EC 3.4.24，Atriopeptidase，NEP，SFE，Membrane Metallo-Endopeptidase (Neutral Endopeptidase， Enkephalinase， CALLA， CD10)，Membrane Metallo-Endopeptidase Variant 1，Membrane Metallo-Endopeptidase Variant 2，Neprilysin-390，Neprilysin-411，CD10 Antigen，EC 3.4.24.11，CMT2T，SCA43，EPN，MME，Enkephalinase，CALLA，Neutral endopeptidase，Common acute lymphocytic leukemia antigen，Neprilysin，CD10，Membrane Metalloendopeptidase，Neutral Endopeptidase 24.11，Skin fibroblast elastase
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Neprilysin
Target-Alias	EC:3.4.24.11，EC 3.4.24，Atriopeptidase，NEP，SFE，Membrane Metallo-Endopeptidase (Neutral Endopeptidase， Enkephalinase， CALLA， CD10)，Membrane Metallo-Endopeptidase Variant 1，Membrane Metallo-Endopeptidase Variant 2，Neprilysin-390，Neprilysin-411，CD10 Antigen，EC 3.4.24.11，CMT2T，SCA43，EPN，MME，Enkephalinase，CALLA，Neutral endopeptidase，Common acute lymphocytic leukemia antigen，Neprilysin，CD10，Membrane Metalloendopeptidase，Neutral Endopeptidase 24.11，Skin fibroblast elastase
Anzahl der inverkehr gebrachten Arzneimittel	3
Anzahl der klinischen Arzneimittel	8
Höchste Forschungs- und Entwicklungsphase	Approved

Neprilysin Produktliste

Attribut
Protein (3)
Produktbibliothek
Online (3)
Spezies
Human (3)
Etikett
Fc Tag (1)Tag Free (1)His Tag (1)
Marker
Unconjugated (3)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
MME-H521b	Human	HEK293	Human Neprilysin / MME / CD10 Protein, Tag Free (active enzyme)	In den Warenkorb legen
MME-H5243	Human	HEK293	Human Neprilysin / MME / CD10 Protein, His Tag (active enzyme, MALS verified)	In den Warenkorb legen
MME-H526a	Human	HEK293	Human Neprilysin / MME / CD10 Protein, Fc Tag	In den Warenkorb legen

Gesamtmenge3

Neprilysin Molekülhintergrund

Cluster of differentiation 10 (CD10) is also known as membrane metallo-endopeptidase, neutral endopeptidase (NEP), Neprilysin, and common acute lymphoblastic leukemia antigen (CALLA), is a 90-110-kDa type II transmembrane glycoprotein normally expressed by a variety of tissues, including epithelial cells of the prostate, kidney, intestine, endometrium, adrenal glands, and lung. This zinc-dependent metalloprotease enzyme cleaves peptide bonds on the amino side of hydrophobic residues and inactivates a variety of physiologically active secreted peptides. CD20 is thought to be the rate-limiting degrading enzyme of amyloid β peptide (Aβ) whose abnormal misfolding and aggregation in neural tissue has been implicated in the development of Alzheimer's disease (AD). CD10 is also identified as the common acute lymphoblastic leukemia antigen (CALLA) present on leukemic cells of pre-B phenotype, and thus serves as the most important biomarker in the diagnosis of human acute lymphocytic leukemia (ALL).

Neprilysin Molekülalias

MME,CALLA,CD10,DKFZp686O16152,MGC126681,MGC126707,NEP,SFE,Neprilysin

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Dexecadotril		Phase 3 Clinical	Bioprojet Pharma	Gastrointestinal Diseases	Details
Sacubitril/Valsartan (Chong Kun Dang Pharmaceutical)	CKD-202A	Phase 3 Clinical	Chong Kun Dang Pharmaceutical Corp	Essential Hypertension	Details
QR-12000	QR-12000	Phase 3 Clinical	Wuhan Createrna Science and Technology Co Ltd	Essential Hypertension; Hypertension	Details
Debio-0827	PL-37; Debio-0827	Phase 2 Clinical	Pharmaleads	Pain	Details
Sacubitril	AHU-377	Phase 2 Clinical	Novartis Pharma Ag	Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; Diabetes Mellitus; Essential Hypertension; Heart Failure; Hypertension; Insulin Resistance; Metabolic Diseases	Details
Anti-CD10 CAR T-cell therapy (Zhujiang Hospital/Nanfang Hospital)		Phase 1 Clinical	Southern Medical University Zhujing Hospital	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	Details
Sacubitril Valsartan Sodium Extended-Relesae Tablets(Taizhou Overseas Pharma)		Phase 1 Clinical	Taizhou Overseas Pharmaceuticals Co Ltd	Heart Failure	Details
Sacubitril/Allisartan Isoproxil/Amlodipine Besylate		Phase 1 Clinical	Shenzhen Salubris Pharmaceuticals Co Ltd	Essential Hypertension	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Sacubitril/Allisartan Isoproxil	AHU-377/EXP3174; S-086	Approved	Shenzhen Salubris Pharmaceuticals Co Ltd	信超妥	Mainland China	Essential Hypertension	Shenzhen Salubris Pharmaceuticals Co Ltd	2025-05-20	Essential Hypertension; Heart Failure; Hypertension	Details
Sacubitril/Valsartan Sodium Hydrate	LCZ-696; LCZ-696A	Approved	Novartis Pharma Ag	ENTRESTO SPRINKLE, Enresuto, Enrest, Entresto, Neparvis, 诺欣妥, 科畅欣	United States	Heart Failure	Novartis Pharmaceuticals Corp	2015-07-07	Breast Neoplasms; Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; Coronavirus Disease 2019 (COVID-19); Erectile Dysfunction; Essential Hypertension; Heart Defects, Congenital; Heart Diseases; Heart Failure; Heart Failure, Diastolic; Heart Failure, Systolic; Hepatic Insufficiency; Hypertension; Lymphoma; Myocardial Infarction; Obesity; Peripheral Arterial Disease; Postmyocardial Infarction Syndrome; Renal Insufficiency; Renal Insufficiency, Chronic; Ventricular Dysfunction, Left	Details
Racecadotril	Tiorfan; Hidrasec	Approved	Bioprojet Pharma		France	Diarrhea	Bioprojet Pharma	1993-03-23	Diarrhea; Diarrhea, Infantile; Sepsis	Details